DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation study

Uri Kopylov(Sheba Medical Center), Marc Ferrante(Universitair Ziekenhuis Leuven), Nikolaos Kamperidis(St Mark's Hospital), Xavier Roblin(Centre Hospitalier Universitaire de Saint-Étienne), E I Tsoukal(Evangelismos Hospital), Gionata Fiorino(Carlo Forlanini Hospital), Ariella Bar‐Gil Shitrit, Taina Sipponen(University of Helsinki), Dimitrios Christodoulou(University of Ioannina), Naila Arebi, Peter Bossuyt(Imelda Hospital), Irit Avni‐Biron, Christian Maaser(Klinikum Lüneburg), Iris Dotan(Tel Aviv University), Britta Siegmund(Humboldt-Universität zu Berlin), Torsten Kucharzik(Klinikum Lüneburg), Luc Biedermann(University of Zurich), Bram Verstockt(Universitair Ziekenhuis Leuven), Laurent Peyrin‐Biroulet(Délégation Centre-Est), P Steinhagen(Humboldt-Universität zu Berlin), Shaji Sebastian(University of Hull), Alessandro Armuzzi, DC Baumgart(Radboud University Nijmegen), Tim Raine(National Health Service), Shomron Ben‐Horin(Tel Aviv University), Bella Ungar(Sheba Medical Center), Henit Yanai(Tel Aviv University), Sandro Ardizzone(European CanCer Organisation), Marina Coletta(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Daniela Pugliese(Agostino Gemelli University Polyclinic), Mariangela Allocca(Vita-Salute San Raffaele University), Nitsan Maharshak(Yale University), Elena Sonnenberg(Charité - Universitätsmedizin Berlin), Gerasimos Mantzaris(Evangelismos Hospital), Rami Eliakim(Sheba Medical Center), Yulia Ron(Tel Aviv University), K.H. Katsanos, Pauliina Molander(University of Helsinki)
Journal of Crohn s and Colitis
January 16, 2018
Cited by 4


Related Papers